Scan to Download ios&Android APP

Trade Galectin Therapeutics Inc. - GALT CFD

2.03
1.5%
0.08
Low: 1.93
High: 2.09
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 2
Open* 1.93
Day's Range* 1.93 - 1.93
1-Year Change* -3.98%
Volume N/A
Average Vol. (3m) 2.01397
52 wk Range N/A
Market Cap 119.074
P/E Ratio N/A
Shares Outstanding 59388500
Revenue N/A
EPS -0.5802
Dividend (Yield %) N/A
Beta 1.88773
Next Earnings Date Aug 15, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 11, 2022 2.00 0.07 3.63% 1.93 2.01 1.92
Aug 10, 2022 1.97 0.07 3.68% 1.90 2.03 1.90
Aug 9, 2022 1.91 -0.15 -7.28% 2.06 2.08 1.88
Aug 8, 2022 2.12 -0.02 -0.93% 2.14 2.21 2.08
Aug 5, 2022 2.15 -0.06 -2.71% 2.21 2.22 2.10
Aug 4, 2022 2.13 0.01 0.47% 2.12 2.17 2.09
Aug 3, 2022 2.14 -0.05 -2.28% 2.19 2.25 2.13
Aug 2, 2022 2.19 -0.01 -0.45% 2.20 2.25 2.19
Aug 1, 2022 2.23 -0.02 -0.89% 2.25 2.26 2.21
Jul 29, 2022 2.22 -0.28 -11.20% 2.50 2.52 2.19
Jul 28, 2022 2.45 0.36 17.22% 2.09 2.45 2.08
Jul 27, 2022 2.05 -0.05 -2.38% 2.10 2.14 2.03
Jul 26, 2022 1.99 -0.20 -9.13% 2.19 2.20 1.98
Jul 25, 2022 2.10 0.22 11.70% 1.88 2.16 1.84
Jul 22, 2022 1.82 0.09 5.20% 1.73 1.83 1.73
Jul 21, 2022 1.73 0.03 1.76% 1.70 1.73 1.70
Jul 20, 2022 1.72 0.07 4.24% 1.65 1.77 1.65
Jul 19, 2022 1.65 0.05 3.12% 1.60 1.67 1.60
Jul 18, 2022 1.59 0.02 1.27% 1.57 1.62 1.57
Jul 15, 2022 1.63 -0.03 -1.81% 1.66 1.67 1.57

Galectin Therapeutics Inc. Events

Time (UTC) Country Event
Monday, August 15, 2022
10:59
  US
Q2 2022 Galectin Therapeutics Inc Earnings Release
Monday, November 14, 2022
13:30
  US
Q3 2022 Galectin Therapeutics Inc Earnings Release
Friday, December 2, 2022
16:00
  US
Galectin Therapeutics Inc Annual Shareholders Meeting
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 0 0 0 0 0 0
Total Operating Expense 21.481 16.247 13.602 13.438 23.444 30.179
Selling/General/Admin. Expenses, Total 6.156 4.526 7.131 5.971 5.468 6.361
Research & Development 15.325 11.721 6.471 7.467 17.976 23.818
Operating Income -21.481 -16.247 -13.602 -13.438 -23.444 -30.179
Interest Income (Expense), Net Non-Operating 0.045 0.012 -0.298 0.144 -0.021 -0.348
Net Income Before Taxes -21.436 -16.235 -13.9 -13.294 -23.465 -30.527
Net Income After Taxes -21.436 -16.235 -13.9 -13.294 -23.465 -30.527
Net Income Before Extra. Items -21.436 -16.235 -13.9 -13.294 -23.465 -30.527
Net Income -21.436 -16.235 -13.9 -13.294 -23.465 -30.527
Total Adjustments to Net Income -0.914 -1.232 -1.147 -6.885 -0.137 -0.171
Income Available to Common Excl. Extra. Items -22.35 -17.467 -15.047 -20.179 -23.602 -30.698
Income Available to Common Incl. Extra. Items -22.35 -17.467 -15.047 -20.179 -23.602 -30.698
Diluted Net Income -22.35 -17.467 -15.047 -20.179 -23.602 -30.698
Diluted Weighted Average Shares 29.216 35.521 39.414 52.238 57.029 58.527
Diluted EPS Excluding Extraordinary Items -0.76499 -0.49174 -0.38177 -0.38629 -0.41386 -0.52451
Diluted Normalized EPS -0.76499 -0.49174 -0.38177 -0.38629 -0.41386 -0.52451
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 0 0 0 0 0
Total Operating Expense 6.317 8.193 8.244 7.425 9.935
Selling/General/Admin. Expenses, Total 1.418 1.743 1.631 1.569 1.877
Research & Development 4.899 6.45 6.613 5.856 8.058
Operating Income -6.317 -8.193 -8.244 -7.425 -9.935
Interest Income (Expense), Net Non-Operating -0.021 -0.256 -0.276 0.204 0.003
Net Income Before Taxes -6.338 -8.449 -8.52 -7.221 -9.932
Net Income After Taxes -6.338 -8.449 -8.52 -7.221 -9.932
Net Income Before Extra. Items -6.338 -8.449 -8.52 -7.221 -9.932
Net Income -6.338 -8.449 -8.52 -7.221 -9.932
Total Adjustments to Net Income -0.002 -0.065 -0.037 -0.067 0.016
Income Available to Common Excl. Extra. Items -6.34 -8.514 -8.557 -7.288 -9.916
Income Available to Common Incl. Extra. Items -6.34 -8.514 -8.557 -7.288 -9.916
Diluted Net Income -6.34 -8.514 -8.557 -7.288 -9.916
Diluted Weighted Average Shares 57.132 58.312 59.29 59.349 59.354
Diluted EPS Excluding Extraordinary Items -0.11097 -0.14601 -0.14432 -0.1228 -0.16707
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.11097 -0.14601 -0.14432 -0.1228 -0.16707
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 15.794 3.819 8.832 48.209 29.465 41.82
Cash and Short Term Investments 15.362 3.053 8.253 47.48 27.142 39.648
Cash & Equivalents 15.362 3.053 8.253 47.48 27.142 39.648
Prepaid Expenses 0.432 0.766 0.579 0.729 2.323 2.172
Total Assets 15.795 4.161 9.006 48.467 29.6 41.827
Property/Plant/Equipment, Total - Net 0 0 0 0.084 0.048 0.007
Property/Plant/Equipment, Total - Gross 0.074 0.074 0.074 0.158 0.122 0.081
Accumulated Depreciation, Total -0.074 -0.074 -0.074 -0.074 -0.074 -0.074
Intangibles, Net 0.001 0 0
Total Current Liabilities 3.78 2.968 2.108 2.82 5.399 9.033
Accounts Payable 0.91 0.608 0.297 1.661 1.292 1.805
Accrued Expenses 2.802 2.292 1.512 1.093 4.042 7.163
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 0.068 0.068 0.299 0.066 0.065 0.065
Total Liabilities 3.78 2.968 2.108 2.872 5.407 39.211
Total Long Term Debt 0 0 0 0 0 29.048
Total Equity 12.015 1.193 6.898 45.595 24.193 2.616
Redeemable Preferred Stock 2.28 2.28 2.26 2.26 2.25 2.25
Preferred Stock - Non Redeemable, Net 6.682 6.682 6.682
Common Stock 0.033 0.036 0.041 0.056 0.056 0.059
Additional Paid-In Capital 166.721 173.363 194.13 259.673 261.883 271.001
Retained Earnings (Accumulated Deficit) -163.701 -181.168 -196.215 -216.394 -239.996 -270.694
Total Liabilities & Shareholders’ Equity 15.795 4.161 9.006 48.467 29.6 41.827
Total Common Shares Outstanding 32.9129 35.7894 41.1909 56.8946 57.0771 59.3413
Total Preferred Shares Outstanding 6.88568 6.88568 6.83568 1.32768 1.30268 1.30268
Other Long Term Assets, Total 0.342 0.174 0.174 0.087
Other Liabilities, Total 0.052 0.008 1.13
Long Term Debt 29.048
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 22.794 33.334 37.998 41.82 33.507
Cash and Short Term Investments 20.76 31.598 36.6 39.648 31.606
Cash & Equivalents 20.76 31.598 36.6 39.648 31.606
Prepaid Expenses 2.034 1.736 1.398 2.172 1.901
Total Assets 22.897 33.405 38.038 41.827 33.615
Property/Plant/Equipment, Total - Net 0.038 0.028 0.018 0.007 0.108
Other Long Term Assets, Total 0.065 0.043 0.022
Total Current Liabilities 4.663 6.054 8.299 9.033 9.535
Accounts Payable 0.382 0.924 1.917 1.805 1.906
Accrued Expenses 4.281 5.065 6.382 7.163 7.629
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0 0.065 0 0.065 0
Total Liabilities 4.663 16.289 28.789 39.211 39.808
Total Long Term Debt 0 9.643 19.299 29.048 29.275
Other Liabilities, Total 0 0.592 1.191 1.13 0.998
Total Equity 18.234 17.116 9.249 2.616 -6.193
Redeemable Preferred Stock 2.25 2.25 2.25 2.25 2.25
Common Stock 0.056 0.059 0.059 0.059 0.059
Additional Paid-In Capital 262.264 269.657 270.347 271.001 272.108
Retained Earnings (Accumulated Deficit) -246.336 -254.85 -263.407 -270.694 -280.61
Total Liabilities & Shareholders’ Equity 22.897 33.405 38.038 41.827 33.615
Total Common Shares Outstanding 57.1867 59.275 59.3413 59.3413 59.3885
Total Preferred Shares Outstanding 1.30268 1.30268 1.30268 1.30268 1.30268
Long Term Debt 9.643 19.299 29.048 29.275
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -21.436 -16.235 -13.9 -13.294 -23.465 -30.527
Cash From Operating Activities -16.409 -15.892 -10.179 -10.848 -20.601 -24.308
Cash From Operating Activities 0.007 0.001 0
Non-Cash Items 2.479 1.146 4.793 1.805 1.922 2.468
Changes in Working Capital 2.541 -0.804 -1.072 0.641 0.942 3.751
Cash From Investing Activities 0 0 0 0
Capital Expenditures 0 0 0
Cash From Financing Activities 5.925 3.583 15.379 50.075 0.263 36.814
Issuance (Retirement) of Stock, Net 5.925 3.583 15.379 50.469 0.263 6.814
Net Change in Cash -10.484 -12.309 5.2 39.227 -20.338 12.506
Total Cash Dividends Paid -0.394 0
Other Investing Cash Flow Items, Total 0
Issuance (Retirement) of Debt, Net 30
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -6.338 -14.787 -23.306 -30.527 -9.932
Cash From Operating Activities -6.382 -12.359 -17.357 -24.308 -8.042
Non-Cash Items 0.286 1.134 2.007 2.468 0.719
Changes in Working Capital -0.33 1.294 3.942 3.751 1.171
Cash From Financing Activities 0 16.815 26.815 36.814 0
Issuance (Retirement) of Stock, Net 0 6.815 6.815 6.814 0
Net Change in Cash -6.382 4.456 9.458 12.506 -8.042
Issuance (Retirement) of Debt, Net 10 20 30

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

Galectin Therapeutics Inc. Company profile

About Galectin Therapeutics Inc

Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 49% to $23.4M. Higher net loss reflects Research and development increase of 58% to $17.7M (expense), Other General and administrative increase of 15% to $3.6M (expense), Stock-based Compensation in SGA increase of 38% to $1.2M (expense).

Equity composition

Common Stock $.001 Par, 03/12, 300M auth., 12,842,850 issd. Insiders own 18.44%. Ser. A Pref. Stock 5M auth., 1,592,500 issd. Redeemable convt. Pref. stock Ser. B-1 900,000 auth., 900,000 issd. Ser. B-2 2.1M auth., 2,100,000 issd. PO 12/13/01, 1,428,572 shares @ $3.50by Atlas Capital Services LLC. 03/12. 1-for-6 Reverse split.

Industry: Biotechnology & Medical Research (NEC)

Suite 240
4960 Peachtree Industrial Boulevard
NORCROSS
GEORGIA 30071
US

Income statement

People Also Watch

US Crude Oil Spot

91.34 Price
-2.150% 1D Chg, %
Long position overnight fee 0.0139%
Short position overnight fee -0.0312%
Overnight fee time 21:00 (UTC)
Spread 0.03

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading